MX367316B - Inhibidores espirociclicos de catepsina c. - Google Patents

Inhibidores espirociclicos de catepsina c.

Info

Publication number
MX367316B
MX367316B MX2017003156A MX2017003156A MX367316B MX 367316 B MX367316 B MX 367316B MX 2017003156 A MX2017003156 A MX 2017003156A MX 2017003156 A MX2017003156 A MX 2017003156A MX 367316 B MX367316 B MX 367316B
Authority
MX
Mexico
Prior art keywords
cathepsin
inhibitors
same
spirocyclic
spirocyclic inhibitors
Prior art date
Application number
MX2017003156A
Other languages
English (en)
Other versions
MX2017003156A (es
Inventor
Grauert Matthias
Pautsch Alexander
Grundl Marc
Vintonyak Viktor
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2017003156A publication Critical patent/MX2017003156A/es
Publication of MX367316B publication Critical patent/MX367316B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la Fórmula (I) en donde A y Cy tienen uno de los significados indicados en la memoria descriptiva y su uso como inhibidores de catepsina C, composiciones farmacéuticas que los contienen y métodos para utilizarlos como agentes para el tratamiento y/o prevención de enfermedades relacionadas con la actividad de dipeptidil peptidasa I, por ejemplo, enfermedades respiratorias.
MX2017003156A 2014-09-12 2015-09-08 Inhibidores espirociclicos de catepsina c. MX367316B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12
PCT/EP2015/070449 WO2016038007A1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Publications (2)

Publication Number Publication Date
MX2017003156A MX2017003156A (es) 2017-05-23
MX367316B true MX367316B (es) 2019-08-15

Family

ID=51535355

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003156A MX367316B (es) 2014-09-12 2015-09-08 Inhibidores espirociclicos de catepsina c.
MX2019009695A MX2019009695A (es) 2014-09-12 2017-03-09 Inhibidores espirociclicos de catepsina c.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019009695A MX2019009695A (es) 2014-09-12 2017-03-09 Inhibidores espirociclicos de catepsina c.

Country Status (34)

Country Link
US (3) US9540373B2 (es)
EP (2) EP3511331A1 (es)
JP (2) JP2017526716A (es)
KR (1) KR102510588B1 (es)
CN (2) CN108047240B (es)
AP (1) AP2017009733A0 (es)
AU (1) AU2015314355B2 (es)
BR (1) BR112017003433B1 (es)
CA (1) CA2960916C (es)
CL (1) CL2017000432A1 (es)
CO (1) CO2017002268A2 (es)
CY (1) CY1123033T1 (es)
DK (1) DK3191487T3 (es)
EA (1) EA031376B1 (es)
ES (1) ES2749009T3 (es)
HK (1) HK1255362A1 (es)
HR (1) HRP20191756T1 (es)
HU (1) HUE047208T2 (es)
IL (1) IL250262B (es)
LT (1) LT3191487T (es)
MX (2) MX367316B (es)
MY (1) MY188382A (es)
NZ (1) NZ728684A (es)
PE (1) PE20170438A1 (es)
PH (1) PH12017500453B1 (es)
PL (1) PL3191487T3 (es)
PT (1) PT3191487T (es)
RS (1) RS59444B1 (es)
SA (1) SA517381064B1 (es)
SG (1) SG11201701633SA (es)
SI (1) SI3191487T1 (es)
TW (1) TWI687424B (es)
UA (1) UA118610C2 (es)
WO (1) WO2016038007A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
NO2699580T3 (es) 2014-01-24 2018-02-24
EP3174879B1 (en) * 2014-08-01 2018-07-18 Boehringer Ingelheim International GmbH Substituted oxetanes and their use as inhibitors of cathepsin c
KR102510588B1 (ko) * 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
CN112055593B (zh) 2018-03-01 2024-04-09 阿斯利康(瑞典)有限公司 药物组合物
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
CN114106005A (zh) * 2020-08-26 2022-03-01 四川海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
KR20230117738A (ko) * 2020-12-04 2023-08-09 레이스톤 바이오파마 컴퍼니 리미티드 카텝신 c의 소분자 억제제 및 이의 의약적 용도
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
ATE409482T1 (de) 2001-03-02 2008-10-15 Merck Frosst Canada Ltd Cathepsincystein-proteasehemmer
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
WO2006096807A1 (en) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
MY156425A (en) * 2006-06-01 2016-02-26 Sanofi Aventis Spirocyclic nitriles as protease inhibitors
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
WO2009047829A1 (ja) 2007-10-12 2009-04-16 Fujitsu Limited Ｉｐ電話自動試験システム及び方法
KR20100098683A (ko) 2007-12-12 2010-09-08 아스트라제네카 아베 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도
KR20120034639A (ko) 2009-05-07 2012-04-12 아스트라제네카 아베 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
EA026102B1 (ru) 2012-04-27 2017-03-31 Глэксо Груп Лимитед МОДУЛЯТОРЫ СВЯЗАННОГО С РЕТИНОИДОМ СИРОТСКОГО РЕЦЕПТОРА ГАММА (RORγ)
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CA2886495C (en) 2012-09-28 2023-09-19 Ignyta, Inc. Azaquinazoline inhibitors of atypical protein kinase c
EP2908806A1 (en) * 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
MY180311A (en) 2012-10-15 2020-11-28 Epizyme Inc Substituted benzene compounds
EA026415B1 (ru) 2012-10-16 2017-04-28 Янссен Фармацевтика Нв Связанные с метиленом хинолиниловые модуляторы ror-гамма-t
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
US9676748B2 (en) 2012-12-21 2017-06-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2895808A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
SG11201507255QA (en) 2013-03-14 2015-10-29 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
CA2903569C (en) * 2013-03-14 2023-04-11 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides and their use as inhibitors of cathepsin c
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP2970252B1 (en) * 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
WO2015165717A1 (en) * 2014-04-29 2015-11-05 Carebay Europe Ltd Device for adjusting needle insertion depth
CN106660409A (zh) 2014-07-03 2017-05-10 普利司通美国轮胎运营有限责任公司 轮辋保护装置的侧壁装饰
EA031679B9 (ru) 2014-09-12 2019-04-30 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Производные тетрагидрохинолина в качестве ингибиторов бромодомена
KR102510588B1 (ko) * 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
AR101696A1 (es) 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Also Published As

Publication number Publication date
SI3191487T1 (sl) 2019-12-31
LT3191487T (lt) 2019-10-10
JP2018044011A (ja) 2018-03-22
US20160075704A1 (en) 2016-03-17
PH12017500453A1 (en) 2017-07-31
UA118610C2 (uk) 2019-02-11
MX2019009695A (es) 2019-10-07
JP6360961B2 (ja) 2018-07-18
US9540373B2 (en) 2017-01-10
KR102510588B1 (ko) 2023-03-17
RS59444B1 (sr) 2019-11-29
CA2960916A1 (en) 2016-03-17
CL2017000432A1 (es) 2017-10-20
HK1255362A1 (zh) 2019-08-16
CO2017002268A2 (es) 2017-06-20
USRE47636E1 (en) 2019-10-08
NZ728684A (en) 2022-09-30
WO2016038007A1 (en) 2016-03-17
MX2017003156A (es) 2017-05-23
CN108047240B (zh) 2020-08-04
KR20170054489A (ko) 2017-05-17
CN108047240A (zh) 2018-05-18
AU2015314355A1 (en) 2017-02-16
CA2960916C (en) 2023-03-07
PT3191487T (pt) 2019-11-18
TW201625647A (zh) 2016-07-16
SA517381064B1 (ar) 2021-02-07
EP3191487B1 (en) 2019-08-07
EA031376B1 (ru) 2018-12-28
PH12017500453B1 (en) 2017-07-31
EA201790576A1 (ru) 2017-08-31
MY188382A (en) 2021-12-07
US20170073352A1 (en) 2017-03-16
ES2749009T3 (es) 2020-03-18
CY1123033T1 (el) 2021-10-29
EP3191487A1 (en) 2017-07-19
IL250262A0 (en) 2017-03-30
DK3191487T3 (da) 2019-10-28
IL250262B (en) 2020-03-31
AU2015314355B2 (en) 2019-06-20
AP2017009733A0 (en) 2017-02-28
CN107074870A (zh) 2017-08-18
PL3191487T3 (pl) 2020-03-31
CN107074870B (zh) 2019-07-12
SG11201701633SA (en) 2017-03-30
EP3511331A1 (en) 2019-07-17
PE20170438A1 (es) 2017-04-28
HRP20191756T1 (hr) 2019-12-27
BR112017003433B1 (pt) 2023-11-14
TWI687424B (zh) 2020-03-11
US9879026B2 (en) 2018-01-30
JP2017526716A (ja) 2017-09-14
BR112017003433A2 (pt) 2017-11-28
HUE047208T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
PH12017500453B1 (en) Spirocyclic inhibitors of cathepsin c
MX2020006438A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1.
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12017501921A1 (en) Novel compounds
PH12016501750A1 (en) Human plasma kallikrein inhibitors
TN2015000278A1 (en) Autotaxin inhibitors
NZ720478A (en) Autotaxin inhibitor compounds
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
TW201613578A (en) Pharmaceutical combinations
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
PH12014502065A1 (en) Vesicular formulations
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

Legal Events

Date Code Title Description
FG Grant or registration